Mergers & Acquisitions
Price is what you pay, value is what you get.
M&A transactions in biopharma require an extraordinary range of expertise in diverse fields of law – ranging across corporate, intellectual property, regulatory, employment, benefits, dispute, and compliance matters.
We represent buyers and sellers in life science deals of all sizes. Our attorneys have advised biotech clients in many small to midsized M&A transactions and asset acquisitions, but have also worked on some of the largest, most prominent M&A deals in the pharma and biotech industries to date – so we know what issues to look out for, and how to solve them both creatively and efficiently, irrespective of deal volumes.
Our M&A capabilities for life sciences clients include:
​
-
Planning and conducting comprehensive due diligence, including sector-specific issues such as regulatory approvals and permits, IP and licenses, business compliance, and commercial contracts
-
Creating and implementing deal structures for domestic and cross-border mergers, acquisitions, divestitures, spin-offs, carve-outs, restructurings, and joint ventures, taking into account regulatory specifics
-
Drafting and negotiating deal terms, ranging from the ‘master’ sale and purchase agreement to a variety of sector-specific ‘ancillary’ agreements, such as (cross-)licensing agreements, contract manufacturing agreements, marketing and distribution agreements, transitional service agreements et. al.
-
Structuring and negotiating sector-specific provisions such as earn-outs, milestone payments and royalties